Lysosomal Therapeutics Overview
- Year Founded
-
2011
- Status
-
Acquired/Merged
- Employees
-
12
- Latest Deal Type
-
M&A
Lysosomal Therapeutics General Information
Description
Developer of therapies designed for patients with severe neurological diseases affecting movement, cognition and general health. The company is dedicated to innovative, research and development in the field of neurodegeneration and leverages the genetically and clinically validated link between lysosomal disorders and neurodegenerative diseases to establish a unique and effective platform for novel drug discovery, enabling physicians to treat a disease like Parkinson.
Contact Information
Website
www.lysosomaltx.comCorporate Office
- 19 Blackstone Street
- Cambridge, MA 02139
- United States
Corporate Office
- 19 Blackstone Street
- Cambridge, MA 02139
- United States
Lysosomal Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 01-Oct-2020 | Completed | Generating Revenue | |||
| 5. Later Stage VC | 07-Nov-2019 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A) | 13-Jan-2017 | Completed | Product Development | |||
| 3. Merger/Acquisition | 09-Jan-2017 | Cancelled | Product Development | |||
| 2. Grant | 05-Dec-2014 | $230K | $4.8M | Completed | Product Development | |
| 1. Seed Round | 30-Apr-2014 | $4.8M | $4.8M | Completed | Product Development |
Lysosomal Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Seed |
Lysosomal Therapeutics Comparisons
Industry
Financing
Details
Lysosomal Therapeutics Competitors (23)
One of Lysosomal Therapeutics’s 23 competitors is Akelos, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Akelos | Venture Capital-Backed | New York, NY | ||||
| Alzheon | Venture Capital-Backed | Framingham, MA | ||||
| Cerecin | Venture Capital-Backed | Broomfield, CO | ||||
| Compass Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA |
Lysosomal Therapeutics Patents
Lysosomal Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2019126776-A1 | Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof | Inactive | 21-Dec-2017 | ||
| JP-2021506920-A | Crystalline substituted cyclohexylpyrazolo [1,5-a] pyrimidinylcarboxamide compounds and their therapeutic use | Inactive | 21-Dec-2017 | ||
| EP-3452455-A1 | Substituted imdazo[1,2- ]pyridines, substituted imidazo[1,2- ]pyrazines, related compounds, and their use in the treatment of medical disorders | Inactive | 05-May-2016 | ||
| EP-3452455-A4 | Substituted imdazo[1,2- ]pyridines, substituted imidazo[1,2- ]pyrazines, related compounds, and their use in the treatment of medical disorders | Inactive | 05-May-2016 | ||
| WO-2017192931-A1 | Substituted imdazo[1,2-α]pyridines, substituted imidazo[1,2-α]pyrazines, related compounds, and their use in the treatment of medical disorders | Inactive | 05-May-2016 | C07D471/04 |
Lysosomal Therapeutics Signals
Lysosomal Therapeutics Former Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Atlas Venture | Venture Capital | Minority | ||
| Gray Ventures | Venture Capital | Minority | ||
| Hatteras Venture Partners | Venture Capital | Minority | ||
| Lilly Ventures | Corporate Venture Capital | Minority | ||
| Mass General Brigham Ventures | Venture Capital | Minority |
Lysosomal Therapeutics FAQs
-
When was Lysosomal Therapeutics founded?
Lysosomal Therapeutics was founded in 2011.
-
Where is Lysosomal Therapeutics headquartered?
Lysosomal Therapeutics is headquartered in Cambridge, MA.
-
What is the size of Lysosomal Therapeutics?
Lysosomal Therapeutics has 12 total employees.
-
What industry is Lysosomal Therapeutics in?
Lysosomal Therapeutics’s primary industry is Drug Discovery.
-
Is Lysosomal Therapeutics a private or public company?
Lysosomal Therapeutics is a Private company.
-
What is Lysosomal Therapeutics’s current revenue?
The current revenue for Lysosomal Therapeutics is .
-
How much funding has Lysosomal Therapeutics raised over time?
Lysosomal Therapeutics has raised $31.9M.
-
Who are Lysosomal Therapeutics’s investors?
Atlas Venture, Gray Ventures, Hatteras Venture Partners, Lilly Ventures, and Mass General Brigham Ventures are 5 of 8 investors who have invested in Lysosomal Therapeutics.
-
Who are Lysosomal Therapeutics’s competitors?
Akelos, Alzheon, Cerecin, Compass Therapeutics, and Aro Biotherapeutics are some of the 23 competitors of Lysosomal Therapeutics.
-
When was Lysosomal Therapeutics acquired?
Lysosomal Therapeutics was acquired on 01-Oct-2020.
-
Who acquired Lysosomal Therapeutics?
Lysosomal Therapeutics was acquired by Bial.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process